|
Thomas' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Acadia revises Alzheimer’s psychosis trials, an FDA panel backs GRAIL’s cancer test, and Atossa’s CEO joins an aging-diseases discussion.
The top 10 stories from Thu Sep 24, 2026 06:57 AM to Fri Sep 25, 2026 06:57 AM
Generated September 25, 2026 at 6:57 AM
|
|
|
#1 XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain Published 2026-09-25 XtalPi submitted a U.S. FDA investigational new drug application for KQTD-126, a gut-restricted pan-TRK inhibitor being developed for chronic intestinal pain. Covered by: prnewswire.com |
#2 Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T Published 2026-09-24 Kyverna Therapeutics reported positive one-year results for CAR-T treatment in stiff person syndrome, supporting its FDA submission for the rare autoimmune disorder. Covered by: endpoints.news |
#3 Overton vows speed, deference to staff reviews, if confirmed to lead FDA Published 2026-09-25 FDA commissioner nominee Overton pledged faster decisions and deference to staff reviews while facing questions about vaccines, abortion drugs, and the agency’s independence. Covered by: biocentury.com, insights.citeline.com |
#4 Elevar wins first FDA approval with second-line drug for bile duct cancer Published 2026-09-24 The FDA approved Elevar Therapeutics’ Lyrfigtu as a second-line treatment for certain bile duct cancer patients, marking the company’s first approval. Covered by: endpoints.news |
#5 Endpoints, Study Duration: EMA Sets Out Evidence Bar For Sickle Cell, Thalassemia Drug Approvals Published 2026-09-24 The EMA outlined evidence requirements, including study endpoints and duration, for approving drugs targeting sickle cell disease and thalassemia. Covered by: insights.citeline.com |
#6 Formycon Points To Benefits For Early Movers On Biosimilar Streamlining Published 2026-09-24 Formycon says early biosimilar developers could benefit as regulators increasingly streamline clinical trial requirements. Covered by: insights.citeline.com |
#7 Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging Published 2026-09-24 Atossa Therapeutics CEO Steven Quay will join a Harvard panel at ARDD 2026 discussing clinical trials and regulatory pathways for diseases of aging. Covered by: prnewswire.com |
#8 FDA Panel Backs GRAIL’s Multi-Cancer Test, But Split Votes Put ‘Early Detection’ Claim In Play Published 2026-09-24 An FDA panel backed GRAIL’s multi-cancer test, but divided votes questioned whether its “early detection” claim demonstrates improved disease outcomes. Covered by: insights.citeline.com |
#9 Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis Published 2026-09-24 Acadia modified Phase III trials for remlifanserin, an investigational treatment for Alzheimer’s-related psychosis, affecting approximately 30% of patients. Covered by: insights.citeline.com |
#10 ‘Not A Numbers Game’: EMA Pushes Back On US FDA’s Single Pivotal Trial Default Standard Published 2026-09-24 The EMA argues pivotal drug approvals should not default to a single trial when multiple studies address distinct scientific questions. Covered by: insights.citeline.com |
